Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

Inclusion Criteria:

- Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to randomisation
(Visit 2)

- Current treatment: metformin monotherapy or metformin in any combination with 1 or 2
other OADs including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl
peptidase IV (DPP-IV) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones
(TZDs) all with unchanged dosing for at least 12 weeks prior to randomisation (Visit
2)-metformin: alone or in combination (including fixed combination) must be at least
1000 mg daily

- HbA1c 7.0-10.0% (both inclusive) by central laboratory analysis

- BMI (Body Mass Index) no higher than 45.0 kg/m^2

Exclusion Criteria:

- Treatment with glucagon-like peptide 1 (GLP-1) receptor agonist within the last 12
weeks prior to Visit 2

- Suffer from a life threatening disease (e.g. cancer)

- Females of childbearing potential who are pregnant (as determined by central
laboratory beta-human chorionic gonadotropin (beta-hCG), breast feeding or intend to
become pregnant or are not using adequate contraceptive methods (adequate
contraceptive methods as required by law or practise [for Germany, adequate
contraceptive methods are: implants, injectables, combined oral contraceptives,
hormonal IUD, sexual abstinence or vasectomised partner])